AIRLINK 196.20 Increased By ▲ 4.36 (2.27%)
BOP 10.16 Increased By ▲ 0.29 (2.94%)
CNERGY 7.92 Increased By ▲ 0.25 (3.26%)
FCCL 38.30 Increased By ▲ 0.44 (1.16%)
FFL 15.90 Increased By ▲ 0.14 (0.89%)
FLYNG 25.44 Increased By ▲ 0.13 (0.51%)
HUBC 130.65 Increased By ▲ 0.48 (0.37%)
HUMNL 13.79 Increased By ▲ 0.20 (1.47%)
KEL 4.66 Decreased By ▼ -0.01 (-0.21%)
KOSM 6.38 Increased By ▲ 0.17 (2.74%)
MLCF 44.95 Increased By ▲ 0.66 (1.49%)
OGDC 209.79 Increased By ▲ 2.92 (1.41%)
PACE 6.68 Increased By ▲ 0.12 (1.83%)
PAEL 41.05 Increased By ▲ 0.50 (1.23%)
PIAHCLA 17.75 Increased By ▲ 0.16 (0.91%)
PIBTL 8.13 Increased By ▲ 0.06 (0.74%)
POWER 9.38 Increased By ▲ 0.14 (1.52%)
PPL 180.99 Increased By ▲ 2.43 (1.36%)
PRL 40.00 Increased By ▲ 0.92 (2.35%)
PTC 24.41 Increased By ▲ 0.27 (1.12%)
SEARL 111.75 Increased By ▲ 3.90 (3.62%)
SILK 0.99 Increased By ▲ 0.02 (2.06%)
SSGC 38.17 Decreased By ▼ -0.94 (-2.4%)
SYM 19.22 Increased By ▲ 0.10 (0.52%)
TELE 8.75 Increased By ▲ 0.15 (1.74%)
TPLP 12.10 Decreased By ▼ -0.27 (-2.18%)
TRG 66.00 Decreased By ▼ -0.01 (-0.02%)
WAVESAPP 12.29 Decreased By ▼ -0.49 (-3.83%)
WTL 1.69 Decreased By ▼ -0.01 (-0.59%)
YOUW 3.99 Increased By ▲ 0.04 (1.01%)
BR100 12,090 Increased By 159.6 (1.34%)
BR30 35,982 Increased By 322.6 (0.9%)
KSE100 114,866 Increased By 1659.2 (1.47%)
KSE30 36,099 Increased By 534 (1.5%)

Gay men at high risk of contracting HIV should have access to a daily dose of a drug used to treat the AIDS-causing virus, but as a preventive measure, researchers recommended on September 10.
The medicine, sold under the brand name Truvada, proved almost 90 percent effective at protecting men taking part in a British study, they wrote in The Lancet medical journal. However, some worry that prescribing it as pre-exposure prophylaxis (PrEP) rather than treatment, would cause a jump in unsafe sex, and with it other sexually transmitted diseases, by removing the fear of contracting HIV. There is also the prohibitive cost: a year's supply of Truvada, in a western European country, would cost around 7,000 euros ($7,700).
"National health services are under financial constraints, but they cannot afford to ignore the results," wrote the study authors, as they officially published the outcome of the study whose results have already been announced elsewhere.
The findings, they added: "strongly support the addition of PrEP to the current standard of prevention for men who have sex with men at risk of HIV infection."
In the 2012-2014 study, Truvada was given to 544 men who reported having had sex with other men in the previous three months without a condom.
Some were given the drug right away and others after a year - the first group had an 86-percent lower risk than the second over the study period.
Researchers also observed no significantly higher risk of sexually transmitted diseases like syphilis among the protected group.
"Many gay men are at imminent risk of catching HIV and this is a way we can stop that," study co-author Sheena McCormack of University College London told AFP. Michael Brady, medical director of the Terrence Higgins Trust, a British anti-HIV/AIDS charity, said the study was "an essential step towards ensuring access to PrEP for those who need it."
The drug has not been universally welcomed in the gay community, eliciting debate about promiscuity, erratic condom use and risks of worsening the stubborn HIV/AIDS epidemic which has killed 36 million people world-wide in the past three decades.
The drug is much less effective if not taken daily, some point out, which means forgetfulness could put your life at risk.

Copyright Agence France-Presse, 2015

Comments

Comments are closed.